Peptide Therapies Offered at Hera Beauty & Wellness
Hera offers six peptide therapies. Each profile covers what the therapy is, what has been studied, the potential benefits researchers are exploring, and the risks. "Potential" means just that: these are areas of research, not expected outcomes.
GHRP (Growth Hormone-Releasing Peptides)
Category: Hormone signaling
What it is: A family of synthetic peptides, such as GHRP-2, GHRP-6, and ipamorelin, that signal the pituitary gland to release the body's own growth hormone.
What has been studied: Short-term human studies show these peptides can raise growth hormone levels. Meaningful health benefits and long-term safety have not been established.
Potential benefits being explored: Body composition, sleep quality, and recovery.
Known and potential risks:
- Increased hunger, water retention, tingling or numbness in the hands, or joint aches
- Rises in blood sugar, cortisol, or prolactin, which vary by peptide
- Not advised with a current or past cancer, or with diabetes unless closely monitored
- Prohibited in competitive sport by the World Anti-Doping Agency (WADA)
Status: Not FDA-approved for these uses. Several growth hormone secretagogues have been the subject of FDA compounding safety reviews.
BPC-157
Category: Tissue recovery
What it is: A synthetic 15-amino-acid peptide based on a protein fragment found in human gastric juice.
What has been studied: Extensive animal research on tendon, ligament, muscle, and gut tissue. Published, controlled human trials are very limited.
Potential benefits being explored: Soft-tissue repair and gut-lining health, based mainly on animal models.
Known and potential risks:
- Injection-site redness, pain, or swelling, plus headache, nausea, or dizziness
- Possible promotion of new blood-vessel growth, a theoretical concern for anyone with a current or past cancer
- Unknown long-term effects in humans
- Prohibited in competitive sport by WADA
Status: Not FDA-approved. Recommended for further review by an FDA advisory committee in July 2026, with final FDA action pending.
TB-500
Category: Tissue recovery
What it is: A synthetic fragment of thymosin beta-4, a protein found in many cells that plays a role in cell movement and repair.
What has been studied: Laboratory and animal studies on wound healing and tissue repair. Human data for the TB-500 fragment itself are lacking.
Potential benefits being explored: Wound healing, flexibility, and recovery of muscle and connective tissue.
Known and potential risks:
- Injection-site reactions, fatigue, headache, or light-headedness
- Not advised with a current or past cancer, because TB-500 influences cell migration and blood-vessel growth
- Unknown long-term safety in humans
- Prohibited in competitive sport by WADA
Status: Not FDA-approved. Recommended for further review by an FDA advisory committee in July 2026, with final FDA action pending.
GHK-Cu (Copper Peptide)
Category: Skin and hair
What it is: A copper-binding peptide that occurs naturally in human plasma, saliva, and urine, and declines with age.
What has been studied: Some small human studies of topical (on-the-skin) use for skin appearance, plus laboratory research. Evidence for the injection of GHK-Cu in humans is lacking.
Potential benefits being explored: Skin firmness and texture, collagen support, wound healing, and hair density.
Known and potential risks:
- Skin irritation with topical use, or injection-site pain, redness, and discoloration
- Not appropriate for people with copper-metabolism disorders such as Wilson's disease
- Unknown long-term effects of injected use
Status: Not FDA-approved. Injectable GHK-Cu is scheduled for FDA advisory committee review before the end of February 2027.
GLOW Peptide Blend
Category: Copper peptide blend for skin and recovery
What it is: A combination product, not a single compound. GLOW blends commonly combine GHK-Cu, BPC-157, and TB-500.
What has been studied: The individual ingredients have been studied as described on this page. The combination itself has not been studied in clinical trials.
Potential benefits being explored: Skin quality and tissue recovery, drawing on the research for each ingredient.
Known and potential risks:
- All of the risks of each ingredient apply
- How the ingredients interact when combined is unknown
- A side effect can be harder to trace to a single ingredient
Status: Not FDA-approved, as a blend or as individual ingredients.
KLOW Peptide Blend
Category: Copper peptide blend for skin, recovery, and inflammation
What it is: A combination product that typically builds on the GLOW formula by adding KPV, a small peptide fragment being studied for its effects on inflammation.
What has been studied: KPV research is mainly laboratory- and animal-based. The other ingredients have been studied as described on this page. The KLOW combination has not been studied in clinical trials.
Potential benefits being explored: Skin quality, tissue recovery, and inflammation support, drawing on the research for each ingredient.
Known and potential risks:
- All of the risks of each ingredient apply, including those of GHK-Cu, BPC-157, and TB-500
- How four ingredients interact when combined is unknown
- A side effect can be harder to trace to a single ingredient
Status: Not FDA-approved, as a blend or as individual ingredients. KPV was recommended for further review by an FDA advisory committee in July 2026, with final FDA action pending.
